Federal regulators want more data before approving new Merck pain &lt;b&gt;...&lt;/b&gt; Most analysts and doctors had not expected the FDA to give Arcoxia a green light now because Merck pulled Vioxx from the market last month after a study showed it doubled patients risk of heart attacks and strokes.